Celebrex Patent Expiration

Celebrex is a drug owned by Upjohn Us 2 Llc. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 02, 2015. Details of Celebrex's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5760068

(Pediatric)

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
Dec, 2015

(8 years ago)

Expired
USRE44048

(Pediatric)

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder
Dec, 2015

(8 years ago)

Expired
US5760068 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
Jun, 2015

(9 years ago)

Expired
USRE44048 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder
Jun, 2015

(9 years ago)

Expired
US5563165

(Pediatric)

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
May, 2014

(10 years ago)

Expired
US5466823

(Pediatric)

Substituted pyrazolyl benzenesulfonamides
May, 2014

(10 years ago)

Expired
US5563165 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
Nov, 2013

(10 years ago)

Expired
US5466823 Substituted pyrazolyl benzenesulfonamides
Nov, 2013

(10 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Celebrex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Celebrex's family patents as well as insights into ongoing legal events on those patents.

Celebrex's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Celebrex's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 02, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Celebrex Generic API suppliers:

Celecoxib is the generic name for the brand Celebrex. 24 different companies have already filed for the generic of Celebrex, with Watson Labs Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Celebrex's generic

How can I launch a generic of Celebrex before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Celebrex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Celebrex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Celebrex -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
50 mg 21 Mar, 2008 1 30 May, 2014 14 Apr, 2018 Extinguished
100 mg, 200 mg and 400 mg

Alternative Brands for Celebrex

Celebrex which is used for reducing inflammation and treating various types of arthritis., has several other brand drugs in the same treatment category and using the same active ingredient (Celecoxib). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Azurity
Xatmep Used for treating acute lymphoblastic leukemia and juvenile rheumatoid arthritis.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Celecoxib. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Kowa Pharms
Seglentis
Purple Biotech
Consensi
Scilex Pharms
Elyxyb


Apart from brand drugs containing the same ingredient, some generics have also been filed for Celecoxib, Celebrex's active ingredient. Check the complete list of approved generic manufacturers for Celebrex





About Celebrex

Celebrex is a drug owned by Upjohn Us 2 Llc. It is used for reducing inflammation and treating various types of arthritis. Celebrex uses Celecoxib as an active ingredient. Celebrex was launched by Upjohn in 2006.

Approval Date:

Celebrex was approved by FDA for market use on 15 December, 2006.

Active Ingredient:

Celebrex uses Celecoxib as the active ingredient. Check out other Drugs and Companies using Celecoxib ingredient

Treatment:

Celebrex is used for reducing inflammation and treating various types of arthritis.

Dosage:

Celebrex is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
50MG CAPSULE Prescription ORAL
200MG CAPSULE Prescription ORAL
100MG CAPSULE Prescription ORAL
400MG CAPSULE Prescription ORAL